与选择的比较药物相比,加巴丁的利用率和非治疗用途,美国2013-2022年
Sara Karami1, Jae Wook Yoo1, Corinne Woods1
1Center for Drug Evaluation and Research (CDER), US Food and Drug Administration (FDA), 10903 New Hampshire Avenue, White Oak, Building 22, Silver Spring, MD 20993, USA.
加巴丁非治疗性使用 (NTU) 的危害是显著的,特别是当与阿片类药物结合时. 虽然 gabapentin NTU 病例增加,然后减少,但它们仍然是一个需要关注的公共卫生问题.
科学领域:
- 药物监督 药物监督 药物监督
- 药物使用研究 药物使用研究
- 公共卫生 公共卫生
背景情况:
- 加巴丁的处方量有所增加,部分是为了制阿片类药物的使用.
- 关于加巴丁非治疗用途 (NTU) 危害和趋势的数据有限.
研究的目的:
- 分析 gabapentin 的利用率和 NTU 的趋势.
- 为了将 gabapentin NTU 的危害与pregabalin,diazepam 和 oxycodone 的危害进行比较.
主要方法:
- 使用的处方数据 (2013-2023) 用于药物使用.
- 分析了NTU暴露病例的毒药中心数据 (2013-2022年).
- 用于比较分析的NTU使用率调整后计算的暴露案例率.
主要成果:
- 从2013年到2023年, gabapentin的发行量显著增加.
- 加巴丁NTU病例超过了普雷加巴林和西巴姆,但不超过氧.
- 加巴丁NTU暴露率在2017年达到峰值,随后下降.
- 大多数NTU病例涉及多种物质,特别是阿片类药物,导致严重的后果.
结论:
- gabapentin NTU 存在相当大的公共健康风险.
- 加巴丁与阿片类药物的结合加剧了不良结果.
更多相关视频
07:16Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission
Published on: August 16, 2018
05:45Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells
Published on: October 10, 2025
相关概念视频
Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...
Therapeutic Drug Monitoring: Overview and Classification
Prescription, Nonprescription and Orphan Drugs
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Therapeutic Drug Monitoring: Affecting Factors
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
